Clinicogenomic Landscape of Pancreatic Adenocarcinoma Identifies KRAS Mutant Dosage as Prognostic of Overall Survival

Investigators characterized the genomic and clinical correlates of outcomes in PDAC. They showed that a genomic subtype of KRAS wild-type tumors was associated with early disease onset, distinct somatic and germline features, and significantly better overall survival.